nach oben

Erschienen in:

01.02.2010 | Review

Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?

verfasst von: Anne-Christine Bay-Jensen, Suzi Hoegh-Madsen, Erik Dam, Kim Henriksen, Bodil Cecillie Sondergaard, Philippe Pastoureau, Per Qvist, Morten A. Karsdal

Erschienen in: Rheumatology International | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Osteoarthritis (OA) is a disease of the entire joint. Different treatment strategies for OA have been proposed and tested clinically without the desired efficacy. One reason for the scarcity of current chondroprotective agents may be the insufficient understanding of the patho-physiology of the joint and whether the joint damage is reversible or irreversible. In this review, we compile emerging data on cellular and pathological aspects of OA, and ask whether these data could give clue to when cartilage degradation is reversible and whether a point-of-no-return exists. We highlight different stages of OA, and speculate whether different intervention strategies (e.g. DMOAD vs. SMOADs) may only be efficacious at distinct stages of OA.

Kleemann RU, Krocker D, Cedraro A, Tuischer J, Duda GN (2005) Altered cartilage mechanics and histology in knee osteoarthritis: relation to clinical assessment (ICRS Grade). Osteoarthr Cartil 13:963–985CrossRef

Felson DT, Neogi T (2004) Osteoarthritis: is it a disease of cartilage or of bone? Arthritis Rheum 50:341–344CrossRefPubMed

Hayami T, Pickarski M, Wesolowski GA et al (2004) The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 50:1193–1206CrossRefPubMed

Karsdal MA, Leeming DJ, Dam EB et al (2008) Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthr Cartil 16:638–646CrossRefPubMed

Hayami T, Pickarski M, Zhuo Y, Wesolowski GA, Rodan GA, Duong lT (2006) Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis 2. Bone 38:234–243CrossRefPubMed

Oestergaard S, Rasmussen KE, Doyle N et al (2008) Evaluation of cartilage and bone degradation in a murine collagen antibody-induced arthritis model. Scand J Immunol 67:304–312CrossRefPubMed

Christgau S, Tanko LB, Cloos PA et al (2004) Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 11:508–518CrossRefPubMed

Bagger YZ, Tanko LB, Alexandersen P et al (2005) Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 37:425–430CrossRefPubMed

Karsdal MA, Leeming DJ, Byrjalsen I, Christiansen C (2008) Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation. BMC Musculoskelet Disord 9:153CrossRefPubMed

10.

Martel-Pelletier J, Cloutier JM, Pelletier JP (1990) Cathepsin B and cysteine protease inhibitors in human osteoarthritis. J Orthop Res 8:336–344CrossRefPubMed

11.

Edwards JC (2000) Fibroblast biology. Development and differentiation of synovial fibroblasts in arthritis. Arthritis Res 2:344–347CrossRefPubMed

12.

Martin TJ, Quinn JM, Gillespie MT, Ng KW, Karsdal MA, Sims NA (2006) Mechanisms involved in skeletal anabolic therapies. Ann N Y Acad Sci 1068:458–470CrossRefPubMed

13.

Kong YY, Yoshida H, Sarosi I et al (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323CrossRefPubMed

14.

Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K (2007) Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 22:487–494CrossRefPubMed

15.

Karsdal MA, Neutzsky-Wulff AV, Dziegiel MH, Christiansen C, Henriksen K (2008) Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun 366:483–488CrossRefPubMed

16.

Massicotte F, Aubry I, Martel-Pelletier J, Pelletier JP, Fernandes J, Lajeunesse D (2006) Abnormal insulin-like growth factor 1 signaling in human osteoarthritic subchondral bone osteoblasts 12. Arthritis Res Ther 8:R177CrossRefPubMed

17.

Henrotin Y, Reginster JY (1999) Anabolic events in osteoarthritis 5. Osteoarthr Cartil 7:310–312CrossRefPubMed

18.

Aigner T, Kurz B, Fukui N, Sandell L (2002) Roles of chondrocytes in the pathogenesis of osteoarthritis. Curr Opin Rheumatol 14:578–584CrossRefPubMed

19.

Goldring MB (2006) Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. Best Pract Res Clin Rheumatol 20:1003–1025CrossRefPubMed

20.

Valcourt U, Gouttenoire J, Aubert-Foucher E, Herbage D, Mallein-Gerin F (2003) Alternative splicing of type II procollagen pre-mRNA in chondrocytes is oppositely regulated by BMP-2 and TGF-[beta]1. FEBS Lett 545:115–119CrossRefPubMed

21.

Pfander D, Swoboda B, Kirsch T (2001) Expression of early and late differentiation markers (proliferating cell nuclear antigen, Syndecan-3, Annexin VI, and Alkaline Phosphatase) by human osteoarthritic chondrocytes. Am J Pathol 159:1777–1783PubMed

22.

Reimann I, Mankin HJ, Trahan C (1977) Quantitative histologic analyses of articular cartilage and subchondral bone from osteoarthritic and normal human hips. Acta Orthop Scand 48:63–73PubMedCrossRef

23.

Kronenberg HM (2003) Developmental regulation of the growth plate. Nature 423:332–336CrossRefPubMed

24.

Kamekura S, Kawasaki Y, Hoshi K et al (2006) Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability. Arthritis Rheum 54:2462–2470CrossRefPubMed

25.

Kawaguchi H (2008) Endochondral ossification signals in cartilage degradation during osteoarthritis progression in experimental mouse models. Mol Cells 25:1–6PubMed

26.

Yu L, Liu H, Yan M et al (2007) Shox2 is required for chondrocyte proliferation and maturation in proximal limb skeleton. Dev Biol 306:549–559CrossRefPubMed

27.

Tew SR, Clegg PD, Brew CJ, Redmond CM, Hardingham TE (2007) SOX9 transduction of a human chondrocytic cell line identifies novel genes regulated in primary human chondrocytes and in osteoarthritis. Arthritis Res Ther 9:R107CrossRefPubMed

28.

Akiyama H, Chaboissier MC, Martin JF, Schedl A, de CB (2002) The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 16:2813–2828CrossRefPubMed

29.

Aigner T, Gebhard PM, Schmid E, Bau B, Harley V, Poschl E (2003) SOX9 expression does not correlate with type II collagen expression in adult articular chondrocytes. Matrix Biol 22:363–372CrossRefPubMed

30.

Schaller S, Henriksen K, Hoegh-Andersen P et al (2005) In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 3:553–580CrossRefPubMed

31.

Charni-Ben TN, Garnero P (2007) Monitoring cartilage turnover. Curr Rheumatol Rep 9:16–24CrossRef

32.

Cremers S, Bilezikian JP, Garnero P (2008) Bone markers—new aspects. Clin Lab 54:461–471PubMed

33.

Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Sondergaard BC (2008) Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 10:R63CrossRefPubMed

34.

van Meurs JB, van Lent PL, Holthuysen AE, Singer II, Bayne EK, van den Berg WB (1999) Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum 42:1128–1139CrossRefPubMed

35.

Karsdal MA, Henriksen K, Sorensen MG et al (2005) Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166:467–476PubMed

36.

Behrens F, Kraft EL, Oegema TR Jr (1989) Biochemical changes in articular cartilage after joint immobilization by casting or external fixation. J Orthop Res 7:335–343CrossRefPubMed

37.

Sondergaard BC, Henriksen K, Wulf H et al (2006) Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthr Cartil 14:738–748CrossRefPubMed

38.

Karsdal MA, Sumer EU, Wulf H et al (2007) Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. Arthritis Rheum 56:1549–1558CrossRefPubMed

39.

Mohtai M, Smith RL, Schurman DJ et al (1993) Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest 92:179–185CrossRefPubMed

40.

Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS, Woessner JF Jr (1989) Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 84:678–685CrossRefPubMed

41.

Stoop R, van der Kraan PM, Buma P, Hollander AP, Poole AR, van den Berg WB (1999) Denaturation of type II collagen in articular cartilage in experimental murine arthritis. Evidence for collagen degradation in both reversible and irreversible cartilage damage. J Pathol 188:329–337CrossRefPubMed

Titel: Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?
verfasst von: Anne-Christine Bay-Jensen
Suzi Hoegh-Madsen
Erik Dam
Kim Henriksen
Bodil Cecillie Sondergaard
Philippe Pastoureau
Per Qvist
Morten A. Karsdal
Publikationsdatum: 01.02.2010
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 4/2010
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-009-1183-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Incomplete Kawasaki syndrome followed by systemic onset-juvenile idiopathic arthritis mimicking Kawasaki syndrome

Lupoid sclerosis

Gender differences in the relationship of anti-parvovirus B19 IgG with antinuclear antibody and C-reactive protein in clinical adult serum samples

Clarithromycin in adult-onset Still’s disease: a study of 6 cases

Epidermal growth factor increases prostaglandin E2 production via ERK1/2 MAPK and NF-κB pathway in fibroblast like synoviocytes from patients with rheumatoid arthritis

Rheumatic manifestations of hepatitis B and C and their association with viral load and fibrosis of the liver

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin